IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across publi ...

Company Overview - QIAGEN N.V. has announced a partnership with GENCURIX, Inc. to develop oncology assays for the QIAcuityDx digital PCR platform, marking the first development partner under QIAGEN's QIAcuityDx Partnering Program [1][9] - The collaboration is expected to significantly enhance QIAGEN's Precision Diagnostics business within the Diagnostic Solutions product group [2] Market Position and Financials - QIAGEN has a market capitalization of $10.35 billion and an earnings yield of 5%, which is significantly higher than the industry's -29.3% yield [4] - Over the past year, QIAGEN shares have increased by 8.1%, contrasting with a 16.1% decline in the industry [12] Strategic Initiatives - The QIAcuityDx Partnering Program aims to support third-party assay development, with over 2,700 cumulative placements of the QIAcuityDx platform expected by the end of 2024 [5] - GENCURIX will leverage its expertise in multiplex IVD assay development to create oncology tests, with QIAGEN responsible for marketing these assays globally upon regulatory approval [6][9] Industry Insights - The global IVD market was valued at $108.30 billion in 2024 and is projected to grow at a compound annual growth rate of 5.6% through 2030, driven by demand for accurate and rapid diagnostic solutions [10]

MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that Dr. Kaouthar Lbiati has been named as interim Chief Executive Officer, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for p ...

Core Insights - ProPhase Labs is undergoing significant operational transformations aimed at reducing overhead and aligning resources with high-value opportunities, particularly in the biotech and genomics sectors [5][17] - The company anticipates multiple liquidity events in the coming months, including the potential sale of its subsidiary Nebula Genomics and recovery of insurance payments through Crown Medical Collections [7][10][11] Financial Performance - For Q1 2025, ProPhase reported net revenue of $1.4 million, a decrease from $2.4 million in Q1 2024, primarily due to a $1.0 million drop in consumer products revenue [20] - The cost of revenues for Q1 2025 was $0.9 million, leading to a gross margin profit of $0.5 million, compared to a gross margin loss of $0.1 million in Q1 2024 [21][22] - General and administrative expenses decreased to $4.1 million in Q1 2025 from $7.3 million in Q1 2024, reflecting cost-cutting measures [23] - The net loss from continuing operations for Q1 2025 was $4.7 million, or $(0.13) per share, an improvement from a loss of $5.5 million, or $(0.32) per share, in Q1 2024 [25] Strategic Developments - The company completed the divestiture of its Pharmaloz manufacturing operations for approximately $23 million, saving over $2 million annually [4] - ProPhase is pursuing strategic alternatives for Nebula Genomics, which has a unique 16-petabyte DNA dataset, and expects to receive letters of intent from potential acquirers soon [7][8] - The BE-Smart Esophageal Cancer Test has been submitted for peer review, with commercialization expected later this year, following a favorable ruling on laboratory-developed tests [12][14][16] Cash Flow and Liquidity - As of March 31, 2025, ProPhase had cash and cash equivalents of $88,000, down from $678,000 at the end of 2024, primarily due to cash used in operating activities [26] - The company is optimistic about generating significant cash flow from Crown Medical Collections, which estimates a recovery of approximately $50 million in insurance payments [10][11] Market Position and Future Outlook - ProPhase Labs aims to position itself as a leader in precision diagnostics, particularly in gastroenterology, with its proprietary BE-Smart platform [16] - The company is focused on unlocking value through strategic asset development and disciplined execution, with several major milestones anticipated in the near future [17]

Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth delivered a strong ...